A Signal against the asymptomatic and pre-symptomatic spread of COVID-19
LogicInk is developing a non-invasive, saliva-based COVID-19 genetic biosensor sticker or card – called Signal – that could make it feasible to be applied to the entire world population, at home, frequently.
Think of every household in the world having a small box of LogicInk signals — similar to a box of bandaids.
LogicInk Signals can be sent in advance, and be used easily whenever and as frequently as needed, effectively giving us a shot at the detection of a disease vector as soon as it manifests — for both COVID-19 and the next pandemics to come.
Be the first in the know
Making the invisible visible
We can't effectively solve for what we cannot sense. Countries shut down as the brute force approach for COVID-19 defense, producing dire consequences to our quality of life and functioning of our economies.
With LogicInk's viral RNA Signals, we make the invisible visible, allowing safe reopening of economies for everyone – businesses, employees, and customers.
A Signal that enables safe businesses
Through scalable, fast, and reliable COVID-19 test, LogicInk's viral RNA Signals enables our B2B partners let their customers and employees safely come back to their business – hotels, stadiums, large and small social spaces, offices, etc.
A Signal that entire populations understand
Leveraging its patent-pending wearable wellbeing platform, LogicInk’s new Signal would allow for entire populations to self-administer and interpret results to screen the presence of SARS-CoV-2 RNA (COVID-19) simply by identifying an appropriate color combination. Consumers simply use a special applicator to deposit saliva onto the Signal then place the sticker on a surface to wait for the results.
Presymptomatic and asymptomatic detection
LogicInk Signals focus on signaling early detection, which has been shown to stem the outbreak and transmission of all viruses, including SARS-CoV-2 (COVID-19). Evidence from the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) suggests that COVID-19 can be detected in carriers 1-3 days before their symptoms appear. Presymptomatic and asymptomatic carriers can also unknowingly transmit the virus, making the need for ubiquitous, easily accessible testing critically important.
Easy to mass-produce and mass-distribute: affordable, repeatable test
The test will be repeated as many times as needed, without interaction with medical personnel. Because LogicInk Signals can be efficiently mass-produced and are easy to apply, and do not require any testing cartridges or lateral flow strips, it is financially and logistically feasible to test entire populations for COVID-19. The sensitivity and specificity of the test is designed to be comparable to the gold standard of PCR-based solutions and without requiring a centralized laboratory to be involved. All this is enabling the safe reopening of our economies.
We’re an energetic group of people – chemists, designers, computer scientists, synthetic biologists, physicians, social media experts, filmmakers, and architects – dedicated to the future of health-awareness and body-based self-expression.
LogicInk is funded by West Ventures, market and brand experts with investor discipline; Village Global, the venture firm backed by some of the world’s most successful entrepreneurs including Bill Gates, Jeff Bezos, and Mark Zuckerberg; and Breakout Labs, a fund within the Thiel Foundation.
Along with Berkeley Catalyst Fund, Krillion Ventures, atypical, Mission Bay Capital, Kendall Ventures, Cloudstone Venture Capital, Marta Bulaich, Elizabeth Weil, Yoshihiro Takasawa, Richard Golob, Peter Yared, Antoine Blondeau, John Zhang, Anatoly Tikhman, James Christopherson, and two Fortune 50 officers.